Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBaylor Scott & White Oncology Coverage & Prior Aut…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 219

    Cancer Chemotherapy / Therapy Guidelines

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 219 alerts

    Get alerted when Policy 219 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage criteria for oncology medications and select related therapies for Baylor Scott & White Health Plan members, including criteria for FDA-labeled and compendium-supported uses and requirements for continuation and prior authorization.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyCancer Chemotherapy / Therapy Guidelines
    Policy CodePolicy 219
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateMay 28, 2027
    Key ActionObtain prior authorization for oncology medications in HCPCS ranges A9600-A9699 and J9000-J9999 per plan EOC/SPD.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsmaximum authorization duration
    2 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PD-1/PD-L1 initial max
    A9600-A9699, J9000-J9999applicable HCPCS ranges
    NCCN Cat 1/2Aaccepted compendia

    Coverage Criteria and Clinical Requirements

    Medical necessity criteria

    Covered when ALL of the following are met:

    Primary acceptance criteria: The requested drug is being used for a medically accepted indication defined by one of the following: (a) FDA labeling consistent with product labeling; OR (b) NCCN Drugs & Biologics Compendium Category 1 or 2A; OR (c) acceptable compendia (Thomson Micromedex DrugDex Recommendation Class IIb+ and Efficacy Class IIa+; Clinical Pharmacology 'Strong For'; AHFS-DI supportive narrative; Wolters Kluwer Lexi-Drugs listed as 'Use: Off-Label' with Evidence Level A); OR (d) peer‑reviewed medical literature published in full text in specified journals demonstrating safety and effectiveness for the requested use).

    Abstracts and case reports are excluded; any supporting peer‑reviewed literature for off‑label uses must be supplied.

    Step therapy and prior failure: For oncology medications with a non‑preferred status, the member must have failure of an adequate trial of, or clinically significant intolerance or contraindication to, preferred medications in the same class that can be used for the requested indication (see BSWHP policies 306 and 307).

    Failure of preferred biosimilars does not meet medical necessity for non‑preferred drug requests.

    Dose and frequency are consistent with FDA labeling, NCCN, listed compendia, or indication‑specific peer‑reviewed literature.

    See Appendix A for drug/class specific authorization limits (e.g., PD‑1/PD‑L1 inhibitors for metastatic NSCLC).

    Prior therapy and off‑label review: Requests for drugs previously tried and discontinued for lack of efficacy may be subject to off‑label review unless supported by NCCN or high‑quality peer‑reviewed literature (prospective phase 2/3 studies published as full manuscripts in listed journals).

    Any peer‑reviewed medical literature supporting off‑label use must be submitted with the request.

    Continuation of therapy: For continuation requests, documentation must indicate no evidence of disease progression.

    Approval duration will be the shortest of the clinically appropriate duration, 12 months, or the requested duration.

    Oncology medications and therapies that received FDA accelerated approval but whose indications were subsequently withdrawn by the U.S. Food and Drug Administration are not considered medically necessary. The policy states that clinical benefit for withdrawn accelerated-approval indications has not been established and therefore these uses are excluded from coverage regardless of NCCN, compendia, or peer-reviewed literature status. Authorization duration rules (the shortest of clinically appropriate duration, 12 months, or the requested duration) remain applicable for approved uses.

    Uses designated as NCCN Category 3 are considered unproven and not medically necessary under this policy. The policy treats NCCN Category 1 or 2A recommendations as acceptable bases for medical necessity but explicitly excludes Category 3 recommendations from coverage without further review.

    RegimenIndicationLimit / Authorization

    Billing and Coding

    Applicable HCPCS/HCPCS-J CodesHCPCS
    A9600-A9699HCPCS oncology medications range
    J9000-J9999J-code range for antineoplastic agents
    CPT Codes (not enumerated)CPT
    CPT Codes:CPT codes applicable (not enumerated)
    ICD-10 (not enumerated)ICD-10
    ICD-10 codesRelevant diagnosis codes (not enumerated)
    PD-1/PD-L1 initial therapy duration for metastatic NSCLC — Maximum 2 years
    Regimen scopePD-1/PD-L1 inhibitors for metastatic non-small cell lung cancer (includes agents listed in Appendix A: Bavencio, Imfinzi, Jemperli, Keytruda, Keytruda Qlex, Libtayo, Loqtorzi, Opdivo, Opdivo Qvantig, Opdualag)
    Maximum initial therapy durationMaximum total length of initial therapy is 2 years
    ApplicabilityApplies to initial course of PD-1/PD-L1 inhibitor therapy for metastatic NSCLC; limits described in Appendix A
    Reference sectionSee Appendix A - Drug/Class Limits on Authorization for full agent list and limit details

    Provider Requirements, Prior Authorization, and Denial Triggers

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for oncology medications and therapies billed under HCPCS ranges A9600–A9699 and J9000–J9999, and for other select oncology drugs and interventions covered by this policy. Refer to the member's Evidence of Coverage/Summary Plan Description for plan-specific prior authorization procedures and to applicable Medicare NCDs/LCDs or Texas Medicaid guidance when relevant.

    • Applies to HCPCS codes: A9600–A9699, J9000–J9999
    • Medicare: follow NCD/LCD when available; if none, apply criteria below
    • Medicaid (Texas): confirm coverage per TMHP/TMPPM; HB154 applicable
    Step Therapy

    Step Therapy / Preferred Agent Trial Required

    For non-preferred oncology medications, an adequate trial and failure of preferred medications in the same class — or documented clinically significant intolerance or contraindication — is required prior to approval. See BSWHP Step Therapy policies 306 (Commercial) and 307 (Medicare) for detailed step-therapy rules.

    Background and Rationale

    The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology provide comprehensive, regularly updated treatment guidance developed by multidisciplinary expert panels and apply to the majority of cancer patients. This policy uses NCCN designations to determine acceptable indications: Category 1 or 2A recommendations in the NCCN Drugs & Biologics Compendium support medical necessity, while Category 3 does not. Separately, accelerated approvals granted by the FDA require post-approval verification of clinical benefit; if that benefit is not confirmed and the indication is withdrawn, such accelerated-approval uses are excluded from coverage.

    Key Definitions and Compendia Categories

    NCCN Category 1 definition
    DefinitionRecommendation is based on high-level evidence (e.g., high-powered randomized clinical trials or meta-analyses) and the panel has reached uniform consensus that the recommendation is indicated.
    Evidence standardHigh-level evidence such as randomized controlled trials or meta-analyses
    Consensus requirementUniform (near unanimous) consensus among panel members; may allow some neutral positions
    NCCN Category 2A definition
    DefinitionRecommendation is based on lower-level evidence but there is uniform consensus that the recommendation is appropriate.
    Evidence examplesLower-level evidence may include phase II studies, large cohort studies, case series, or expert/experience-based observations

    Policy Revision History

    2026-06-01policy_effectiveLatest

    Policy updated with new effective date and incorporated oncology coverage criteria and authorization rules (Cancer Chemotherapy / Therapy Guidelines, Policy No. 219).

    2026-05-28policy_review

    Clinical review completed prior to effective date to confirm criteria, continuation requirements, and appendix limits including PD-1/PD-L1 therapy duration for metastatic NSCLC.

    2025-??-??historical_change
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyCancer Chemotherapy / Therapy Guidelines
    Policy CodePolicy 219
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateMay 28, 2027
    Key ActionObtain prior authorization for oncology medications in HCPCS ranges A9600-A9699 and J9000-J9999 per plan EOC/SPD.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsBilling and CodingProvider Requirements, Prior Authorization, and Denial TriggersBackground and RationaleKey Definitions and Compendia CategoriesPolicy Revision History
    • Step-therapy requirement applies when a therapeutically appropriate preferred alternative exists
    • Document prior trials: drug name, dose, duration, outcome, and reason for discontinuation
    Documentation Required

    Documentation Requirements for Authorization

    Requests must include documentation that dosing and frequency are consistent with FDA labeling, NCCN guidance, or accepted compendia, or that peer-reviewed literature supports the requested regimen. For continuation requests, submit evidence of clinical benefit and no disease progression. For off-label uses, include full-text peer-reviewed publications (prospective phase 2/3 or CMS-supported journals) when not supported by FDA/NCCN/compendia.

    • Include full product labeling or NCCN/compendia citation that supports requested dose/frequency
    • For off-label requests, attach full-text articles from accepted journals; abstracts and case reports are excluded
    • See Appendix A for drug/class specific authorization limits (e.g., PD‑1/PD‑L1 inhibitors for metastatic NSCLC)
    Denial Risk

    Denial Triggers / Not Medically Necessary

    Requests for uses that are not FDA‑labeled and not supported by NCCN Category 1 or 2A (or sufficient high‑quality peer‑reviewed evidence) will be denied as not medically necessary. Uses supported only by NCCN Category 2B require detailed literature review and may be subject to denial; Category 3 is considered unproven and not medically necessary. Oncology indications previously granted accelerated approval but subsequently withdrawn by the FDA are not medically necessary.

    • Denial triggers: lack of FDA label AND lack of NCCN Category 1/2A support or adequate peer‑reviewed evidence
    • Category 2B uses require additional review; Category 3 uses are not covered
    • Off‑label requests lacking high‑quality full‑text literature will be denied
    GuidanceRecommendations carry recognition they may be superseded by higher-level evidence as it becomes available

    (Archived entry) Documentation and step-therapy requirements refined; references to compendia and accepted journals clarified.